Psoriatic arthritis - etanercept and infliximab
Etanercept and infliximab for the treatment of psoriatic arthritis
Summary
Etanercept should be offered as an option for treating adults with psoriatic arthritis when: the person has arthritis with three or more tender joints and three or more swollen joints at least two other disease-modifying anti-rheumatic drugs (DMARDs), given on their own or together, haven̵ ...
Erratum
Please note that there is a minor discrepancy between the electronic version of the ‘quick reference guide’ (QRG) on the NICE website and the hard copy version that was mailed to the NHS to arrive on Wednesday 26 July. Section 1.3 of the guidance should read as follows:
1.3 Infliximab, within its licensed indications, is recommended for the treatment of adults with severe active psoriatic arthritis if, under the circumstances outlined in section 1.1, treatment with an anti-TNF (tumour necrosis factor) agent is considered appropriate and the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections.
The electronic version of the QRG that has been published on the NICE website is the correct version. A follow-up mailing to the NHS explaining this error and enclosing a hard copy of the correct version of the QRG will be sent out shortly.
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA104
Issued: July 2006
How this guidance was produced